SynAct Pharma to Participate in Nordic Life Science Days 2025
Kurs
-0,24%
Likviditet
2,86 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-18 | 07:30 | Bokslutskommuniké 2025 |
| 2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2025-05-27 | - | Årsstämma |
| 2025-05-27 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-18 | - | Bokslutskommuniké 2024 |
| 2024-12-13 | - | Extra Bolagsstämma 2024 |
| 2024-10-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-04 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2023-01-12 | - | Extra Bolagsstämma 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-23 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2021-05-21 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-11-08 | - | Extra Bolagsstämma 2019 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-13 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2019-05-10 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2018-05-15 | - | Årsstämma |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced today the company will participate at the Nordic Life Science Days (NLS-Days) on October 13-14, 2025, in Gothenburg, Sweden.
“Nordic Life Science Days is an important platform for engaging with potential partners and investors, and we are excited to engage in discussion on SynAct’s progress and path forward. Our lead program, resomelagon, currently in Phase 2b development, is being investigated in clinical studies in autoimmune diseases and as a host-directed treatment to control hyperinflammatory responses in viral infections. Our most progressed program, Phase 2b study in rheumatoid arthritis, is advancing well and aims to prove the concept of resolution therapy as a new approach to treat patients early with high disease activity. We look forward to meaningful discussions with partners and investors at NLS-Days,” said SynAct Pharma’s Chief Business Officer Mads Liebach Bjerregaard.
To schedule a meeting with SynAct Pharma register at: https://nlsdays.com/partnering/.
The Nordic Life Science Days is an event for Nordic life science with delegates from biotech, medtech, finance and research sectors. Over 1,500 delegates from the Nordics and internationally join with more than 3,000 partnering meetings held over two days.
For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.